On August 30, 2017 Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, reported that data from SL-801’s ongoing Phase 1 trial in patients with advanced solid tumors has been selected by the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) for poster presentation at their Annual Congress 2017, to be held September 8-12, 2017 in Madrid, Spain (Press release, Stemline Therapeutics, AUG 30, 2017, View Source [SID1234520358]). SL-801 is a novel, potent and reversible Exportin-1 (XPO1) inhibitor.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details on the presentation are as follows:
Title: Ongoing Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors; Interim Results
First Author: Judy Wang, MD; Florida Cancer Specialists & Research Institute
Abstract: 406P
Date/Time: Monday, September 11, 2017 – 1:15-2:15 PM CET
Location: Hall 8